Kyle Chenet
Vorstandsvorsitzender bei 410 Medical, Inc.
Aktive Positionen von Kyle Chenet
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
410 Medical, Inc.
410 Medical, Inc. Medical SpecialtiesHealth Technology 410 Medical, Inc. operates as a medical device company. It develops LifeFlow for fluid resuscitation to help patients with life-threatening illnesses such as sepsis. The company was founded by Mark Donald Piehl and Luke Miller Roush in 2013 and is headquartered in Durham, NC. | Direktor/Vorstandsmitglied | - | - |
Vorstandsvorsitzender | - | - | |
Präsident | - | - |
Karriereverlauf von Kyle Chenet
Ehemalige bekannte Positionen von Kyle Chenet
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Biolex Therapeutics, Inc.
Biolex Therapeutics, Inc. Medical DistributorsDistribution Services Biolex Therapeutics, Inc. developed and produced drugs. The company was founded in 1997 and was headquartered in Pittsboro, NC. | Corporate Officer/Principal | 01.07.2005 | - |
Lq3 Pharmaceuticals, Inc.
Lq3 Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Lq3 Pharmaceuticals, Inc. develops innovative oral health therapies. It utilizes PRINT (Particle Replication In Non-Wetting Templates) technology to research and develop solutions for an assortment of oral health issues. The firm's technology offers many advantages, such as tunable release kinetics, targeting, improved drug loading, delivery of biologics and combination products. The company was founded in 2014 and is headquartered in Garland, TX. | Vorstandsvorsitzender | - | - |
GSK PLC | Corporate Officer/Principal | - | - |
Envisia Therapeutics, Inc.
Envisia Therapeutics, Inc. BiotechnologyHealth Technology Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC. | Corporate Officer/Principal | 01.01.2013 | - |
ABBOTT LABORATORIES | Corporate Officer/Principal | - | - |
Liquidia Technologies, Inc.
Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Corporate Officer/Principal | 22.04.2010 | - |
Ausbildung von Kyle Chenet
University of Michigan | Undergraduate Degree |
Stanford University | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 9 |
Vereinigtes Königreich | 2 |
Operativ
Corporate Officer/Principal | 5 |
Chief Executive Officer | 2 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 6 |
Consumer Services | 3 |
Distribution Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ABBOTT LABORATORIES | Health Technology |
GSK PLC | Health Technology |
Private Unternehmen | 5 |
---|---|
Liquidia Technologies, Inc.
Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Health Technology |
Biolex Therapeutics, Inc.
Biolex Therapeutics, Inc. Medical DistributorsDistribution Services Biolex Therapeutics, Inc. developed and produced drugs. The company was founded in 1997 and was headquartered in Pittsboro, NC. | Distribution Services |
Envisia Therapeutics, Inc.
Envisia Therapeutics, Inc. BiotechnologyHealth Technology Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC. | Health Technology |
Lq3 Pharmaceuticals, Inc.
Lq3 Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Lq3 Pharmaceuticals, Inc. develops innovative oral health therapies. It utilizes PRINT (Particle Replication In Non-Wetting Templates) technology to research and develop solutions for an assortment of oral health issues. The firm's technology offers many advantages, such as tunable release kinetics, targeting, improved drug loading, delivery of biologics and combination products. The company was founded in 2014 and is headquartered in Garland, TX. | Health Services |
410 Medical, Inc.
410 Medical, Inc. Medical SpecialtiesHealth Technology 410 Medical, Inc. operates as a medical device company. It develops LifeFlow for fluid resuscitation to help patients with life-threatening illnesses such as sepsis. The company was founded by Mark Donald Piehl and Luke Miller Roush in 2013 and is headquartered in Durham, NC. | Health Technology |
- Börse
- Insiders
- Kyle Chenet
- Erfahrung